In the July 23 edition of Circulation, investigators reported that Octaplex, a four-factor prothrombin complex concentrate (PCC), was faster and safer than fresh frozen plasma; the four-factor PCC was associated with fewer adverse events, faster INR (international normalized ratio) reversal, and less need for red blood cell transfusion.
In a video interview with Neurology Today, Neurology Today Editor-in-Chief Steven P. Ringel, MD, and Associate Editor Robert Holloway Jr., MD, discuss the data in the paper and the pros and cons of accepting the authors’ conclusions in practice. More needs to be studied in terms of the therapy’s cost-effectiveness, the two neurologists agree. But, according to Dr. Holloway, these data provide compelling reasons
why neurologists should check to see whether their pharmacies do have PCC in their formularies. See the full story in the Sept. 19 issue of Neurology Today.